Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$2.33 - $5.07 $414,912 - $902,835
178,074 Added 203.9%
265,408 $631,000
Q2 2023

Aug 14, 2023

SELL
$4.67 - $6.55 $21,472 - $30,116
-4,598 Reduced 5.0%
87,334 $418,000
Q1 2023

May 15, 2023

SELL
$4.95 - $6.09 $100,237 - $123,322
-20,250 Reduced 18.05%
91,932 $521,000
Q4 2022

Feb 14, 2023

SELL
$5.09 - $9.05 $425,977 - $757,385
-83,689 Reduced 42.73%
112,182 $628,000
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $104,534 - $215,042
29,867 Added 17.99%
195,871 $1.26 Million
Q2 2022

Aug 15, 2022

BUY
$2.7 - $7.62 $204,940 - $578,388
75,904 Added 84.24%
166,004 $569,000
Q3 2021

Nov 12, 2021

SELL
$5.46 - $22.6 $86,562 - $358,300
-15,854 Reduced 14.96%
90,100 $627,000
Q2 2021

Aug 12, 2021

BUY
$18.46 - $24.36 $283,434 - $374,023
15,354 Added 16.95%
105,954 $2.53 Million
Q1 2021

May 17, 2021

BUY
$17.66 - $28.92 $60,044 - $98,328
3,400 Added 3.9%
90,600 $1.87 Million
Q4 2020

Feb 03, 2021

BUY
$23.25 - $37.73 $430,125 - $698,005
18,500 Added 26.93%
87,200 $2.14 Million
Q3 2020

Nov 16, 2020

BUY
$3.74 - $28.74 $35,904 - $275,904
9,600 Added 16.24%
68,700 $1.95 Million
Q2 2020

Aug 12, 2020

BUY
$3.04 - $6.2 $8,208 - $16,740
2,700 Added 4.79%
59,100 $281,000
Q1 2020

May 06, 2020

BUY
$2.64 - $3.82 $74,184 - $107,342
28,100 Added 99.29%
56,400 $201,000
Q2 2019

Aug 14, 2019

BUY
$2.28 - $7.35 $1,367 - $4,410
600 Added 2.17%
28,300 $91,000
Q1 2019

May 13, 2019

BUY
$4.83 - $7.21 $30,912 - $46,144
6,400 Added 30.05%
27,700 $190,000
Q4 2018

Feb 11, 2019

BUY
$4.52 - $8.88 $28,475 - $55,944
6,300 Added 42.0%
21,300 $96,000
Q3 2017

Nov 01, 2017

BUY
$12.81 - $16.85 $192,150 - $252,750
15,000
15,000 $241,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.